Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00051948 · ClinicalTrials.gov registry record · Phase 1

TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer

A Phase 1 study, sponsored by Telik.

Completed
Registry status
Phase 1
Development phase
28
Enrollment target

NCT00051948 is a Phase 1 study that has completed, run by Telik. The registered enrollment target is 28 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00051948, a Phase 1 study, has completed, sponsored by Telik.

COMPLETED
Registry status
Phase 1
Development phase
28 participants
Enrollment target

Study Summary

This is a dose-ranging, open label, Phase 1-2a study of TLK286 in combination with Paraplatin (carboplatin) in patients with recurrent ovarian cancer.

Interventions

  • DRUG TLK286

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2003-01
Est. Completion 2005-01
Phase Phase 1

Sponsor

Telik

21 total trials

What the Registry Record Tells You About NCT00051948

The ClinicalTrials.gov registry entry for NCT00051948 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Telik, which has 21 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which TLK286 is the first listed.

NCT00051948 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00051948 about?

NCT00051948 is a clinical study titled "TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer". This is a dose-ranging, open label, Phase 1-2a study of TLK286 in combination with Paraplatin (carboplatin) in patients with recurrent ovarian cancer.

What is the current status of trial NCT00051948?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2003-01. Estimated completion is 2005-01.

What interventions are being tested in trial NCT00051948?

The interventions under investigation include: TLK286 (DRUG).

Who is sponsoring clinical trial NCT00051948?

This trial is sponsored by Telik, which has 21 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.